Parainfluenza viruses

Fields Virology: Sixth Edition

Volumn 1, Issue , 2013, Pages

  Karron, Ruth A ^a   Collins, Peter L ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974698241     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (417)

1. Abinanti FR, Chanock RM, Cook MK, et al. Relationship of human and bovine strains of myxovirus para-influenza 3. Proc Soc Exp Biol Med 1961;106:466-469.
2. Abinanti FR, Hoerlein AB, Watson RL, et al. Serologic studies on myxovirus para-influenza 3 in cattle and the prevalence of antibodies in bovines. J Immunol 1961;86:505-511.
3. Aherne W, Bird T, Court SD, et al. Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 1970;23:7-18.
4. Alamares JG, Elankumaran S, Samal SK, et al. The interferon antagonistic activities of the V proteins from two strains of Newcastle disease virus correlate with their known virulence properties. Virus Res 2010;147:153-157.
5. Alexander D. Classification, host range and distribution of avian paramyxoviruses. In: McFerran JB, McNulty M, eds. Acute Virus Infections in Poultry. Dordrecht: Martinus Nijhoff; 1991:87-95.
6. Alymova IV, Portner A, Takimoto T, et al. The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2005;49:398-405.
7. Ambrose MW, Wyde PR, Ewasyshyn M, et al. Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats. Vaccine 1991;9:505-511.
8. Andrejeva J, Childs KS, Young DF, et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A 2004;101:17264-17269.
9. Andrejeva J, Young DF, Goodbourn S, et al. Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons. J Virol 2002;76:2159-2167.
10. Andrewes CH, Bang FB, Chanock RM, et al. Para-influenza viruses 1, 2, and 3: suggested names for recently described myxoviruses. Virology 1959;8:129-130.
11. Ausejo M, Saenz A, Pham B, et al. The effectiveness of glucocorticoids in treating croup: meta-analysis. BMJ 1999;319:595-600.
12. Bando H, Kawano M, Kondo K, et al. Growth properties and F protein cleavage site sequences of naturally occurring human parainfluenza type 2 viruses. Virology 1991;184:87-92.
13. Bando H, Kondo K, Kawano M, et al. Molecular cloning and sequence analysis of human parainfluenza type 4A virus HN gene: its irregularities on structure and activities. Virology 1990;175:307-312.
14. Bartlett EJ, Cruz AM, Esker J, et al. Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. J Virol 2008;82:8965-8977.
15. Bartlett EJ, Hennessey M, Skiadopoulos MH, et al. Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium. J Virol 2008;82:8059-8070.
16. Baum A, Garcia-Sastre A. Differential recognition of viral RNA by RIG-I. Virulence 2011;2:166-169.
17. Baumgartner WK, Krakowka S, Koestner A, et al. Acute encephalitis and hydrocephalus in dogs caused by canine parainfluenza virus. Vet Pathol 1982;19:79-92.
18. Belshe RB, Hissom FK. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J Med Virol 1982;10:235-242.
19. Belshe RB, Karron RA, Newman FK, et al. Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children. J Clin Microbiol 1992;30:2064-2070.
20. Belshe RB, Newman FK, Tsai TF, et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 2004;189:462-470.
21. Binn LN, Alford JP, Marchwicki RH, et al. Studies of respiratory disease in random-source laboratory dogs: viral infections in unconditioned dogs. Lab Anim Sci 1979;29:48-52.
22. Binn LN, Eddy GA, Lazar EC, et al. Viruses recovered from laboratory dogs with respiratory disease. Proc Soc Exp Biol Med 1967;126:140-145.
23. Bitko V, Musiyenko A, Shulyayeva O, et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005;11:50-55.
24. Bitzer M, Lauer U, Baumann C, et al. Sendai virus efficiently infects cells via the asialoglycoprotein receptor and requires the presence of cleaved F0 precursor proteins for this alternative route of cell entry. J Virol 1997;71:5481-5486.
25. Bjornson CL, Klassen TP, Williamson J, et al. A randomized trial of a single dose of oral dexamethasone for mild croup. N Engl J Med 2004;351:1306-1313.
26. Blumberg BM, Giorgi C, Rose K, et al. Sequence determination of the Sendai virus fusion protein gene. J Gen Virol 1985;66:317-331.
27. Boonyaratanakornkit J, Bartlett E, Schomacker H, et al. The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase R. J Virol 2011;85:1495-1506.
28. Boonyaratanakornkit JB, Bartlett EJ, Amaro-Carambot E, et al. The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection. J Virol 2009;83:1892-1910.
29. Bose S, Basu M, Banerjee AK. Role of nucleolin in human parainfluenza virus type 3 infection of human lung epithelial cells. J Virol 2004;78:8146-8158.
30. Bousse T, Chambers RL, Scroggs RA, et al. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment. Virus Res 2006;121:23-32.
31. Bousse T, Matrosovich T, Portner A, et al. The long noncoding region of the human parainfluenza virus type 1 F gene contributes to the read-through transcription at the M-F gene junction. J Virol 2002;76:8244-8251.
32. Bousse TL, Taylor G, Krishnamurthy S, et al. Biological significance of the second receptor binding site of Newcastle disease virus hemagglutinin-neuraminidase protein. J Virol 2004;78:13351-13355.
33. Brideau RJ, Oien NL, Lehman DJ, et al. Protection of cotton rats against human parainfluenza virus type 3 by vaccination with a chimeric FHN subunit glycoprotein. J Gen Virol 1993;74:471-477.
34. Buchholz CJ, Retzler C, Homann HE, et al. The carboxy-terminal domain of Sendai virus nucleocapsid protein is involved in complex formation between phosphoprotein and nucleocapsid-like particles. Virology 1994;204:770-776.
35. Bukreyev A, Collins PL. Newcastle disease virus as a vaccine vector for humans. Curr Opin Mol Ther 2008;10:46-55.
36. Bukreyev A, Huang Z, Yang L, et al. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 2005;79:13275-13284.
37. Cadd T, Garcin D, Tapparel C, et al. The Sendai paramyxovirus accessory C proteins inhibit viral genome amplification in a promoter-specific fashion. J Virol 1996;70:5067-5074.
38. Caignard G, Komarova AV, Bourai M, et al. Differential regulation of type I interferon and epidermal growth factor pathways by a human Respirovirus virulence factor. PLoS Pathog 2009;5:e1000587.
39. Capua I, Alexander DJ. Human health implications of avian influenza viruses and paramyxoviruses. Eur J Clin Microbiol Infect Dis 2004;23:1-6.
40. Carlos TS, Young DF, Schneider M, et al. Parainfluenza virus 5 genomes are located in viral cytoplasmic bodies whilst the virus dismantles the interferon-induced antiviral state of cells. J Gen Virol 2009;90:2147-2156.
41. Castells E, George VG, Hierholzer JC. NCI-H292 as an alternative cell line for the isolation and propagation of the human paramyxoviruses. Arch Virol 1990;115:277-288.
42. Chakrabarti S, Collingham KE, Holder K, et al. Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy. Clin Infect Dis 2000;31:1516-1518.
43. Chang PC, Hsieh ML, Shien JH, et al. Complete nucleotide sequence of avian paramyxovirus type 6 isolated from ducks. J Gen Virol 2001;82:2157-2168.
44. Chanock R, Johnson K, Cook M. The hemadsorption technique, with special reference to the problem of naturally occuring simian para-influenza viruses. Am Rev Respir Dis 1961;83:125-129.
45. Chanock R, Parrott R. Acute respiratory disease in infancy and childhood: Present understanding and prospects for prevention. Pediatrics 1965;36:21-39.
46. Chanock R, Parrott R, Johnson K, et al. Myxoviruses: parainfluenza. Am Rev Respir Dis 1963;88:152-166.
47. Chanock R, Vargosko A, Luckey A, et al. Association of hemadsorption viruses with respiratory illness in childhood. JAMA 1959;169:548-553.
48. Chanock RM. Association of a new type of cytopathogenic myxovirus with infantile croup. J Exp Med 1956;104:555-576.
49. Chanock RM, Parrott RH, Cook K, et al. Newly recognized myxoviruses from children with respiratory disease. N Engl J Med 1958;258:207-213.
50. Chare ER, Gould EA, Holmes EC. Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses. J Gen Virol 2003;84:2691-2703.
51. Chatziandreou N, Stock N, Young D, et al. Relationships and host range of human, canine, simian and porcine isolates of simian virus 5 (parainfluenza virus 5). J Gen Virol 2004;85:3007-3016.
52. Chen L, Gorman JJ, McKimm-Breschkin J, et al. The structure of the fusion glycoprotein of Newcastle disease virus suggests a novel paradigm for the molecular mechanism of membrane fusion. Structure 2001;9:255-266.
53. Chen YB, Driscoll JP, McAfee SL, et al. Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation. Clin Infect Dis 2011;53(7):e77-e80.
54. Childs K, Stock N, Ross C, et al. MDA-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 2007;359:190-200.
55. Childs KS, Andrejeva J, Randall RE, et al. Mechanism of MDA-5 inhibition by paramyxovirus V proteins. J Virol 2009;83:1465-1473.
56. Chin J, Magoffin RL, Shearer LA, et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969;89:449-463.
57. Chong YL, Padhi A, Hudson PJ, et al. The effect of vaccination on the evolution and population dynamics of avian paramyxovirus-1. PLoS Pathog 2010;6:e1000872.
58. Choppin PW. Multiplication of a myxovirus (SV5) with minimal cytopathic effects and without interference. Virology 1964;23:224-233.
59. Choppin PW, Compans RW. Reproduction of paramyxoviruses. In: Fraenkel-Conrat H, Wagner RR, eds. Comprehensive Virology, vol. 5. New York: Plenum; 1975:95-178.
60. Clements ML, Belshe RB, King J, et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 1991;29:1175-1182.
61. Coelingh KJ, Winter CC, Murphy BR, et al. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J Virol 1986;60:90-96.
62. Coelingh KL. Antigenic variation among human parainfluenza type 3 viruses: Comparative and epidemiologic aspects. In: Kurstak E, Marusyk R, Murphy V, Van Regenmortel M, eds. Applied Virology Research: Virus Variation, vol. 2. New York: Plenum Press; 1989:143-157.
63. Coelingh KV, Winter CC. Naturally occurring human parainfluenza type 3 viruses exhibit divergence in amino acid sequence of their fusion protein neutralization epitopes and cleavage sites. J Virol 1990;64:1329-1334.
64. Collins PL, Bukreyev A, Murphy BR. What are the risks - hypothetical and observed - of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strand RNA viruses? J Virol 2008;82:9805-9806.
65. Collins PL, Hightower LE, Ball LA. Transcriptional map for Newcastle disease virus. J Virol 1980;35:682-693.
66. Compans RW, Choppin PW. Isolation and properties of the helical nucleocapsid of the parainfluenza virus SV5. Proc Natl Acad Sci U S A 1967;57:949-956.
67. Connolly SA, Leser GP, Jardetzky TS, et al. Bimolecular complementation of paramyxovirus fusion and hemagglutinin-neuraminidase proteins enhances fusion: implications for the mechanism of fusion triggering. J Virol 2009;83:10857-10868.
68. Coronel EC, Murti KG, Takimoto T, et al. Human parainfluenza virus type 1 matrix and nucleoprotein genes transiently expressed in mammalian cells induce the release of virus-like particles containing nucleocapsid-like structures. J Virol 1999;73:7035-7038.
69. Craver RD, Gohd RS, Sundin DR, et al. Isolation of parainfluenza virus type 3 from cerebrospinal fluid associated with aseptic meningitis. Am J Clin Pathol 1993;99:705-707.
70. Crennell S, Takimoto T, Portner A, et al. Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat Struct Biol 2000;7:1068-1074.
71. Crowe JE Jr. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis 2001;33:1720-1727.
72. Curran J, Boeck R, Kolakofsky D. The Sendai virus P gene expresses both an essential protein and an inhibitor of RNA synthesis by shuffling modules via mRNA editing. EMBO J 1991;10:3079-3085.
73. Curran J, de Melo M, Moyer S, et al. Characterization of the Sendai virus V protein with an anti-peptide antiserum. Virology 1991;184:108-116.
74. Curran J, Kolakofsky D. Scanning independent ribosomal initiation of the Sendai virus X protein. Embo J 1988;7:2869-2874.
75. Curran J, Marq JB, Kolakofsky D. An N-terminal domain of the Sendai paramyxovirus P protein acts as a chaperone for the NP protein during the nascent chain assembly step of genome replication. J Virol 1995;69:849-855.
76. Curran J, Marq JB, Kolakofsky D. The Sendai virus nonstructural C proteins specifically inhibit viral mRNA synthesis. Virology 1992;189:647-656.
77. Curran JA, Kolakofsky D. Identification of an additional Sendai virus non-structural protein encoded by the P/C mRNA. J Gen Virol 1987;68:2515-2519.
78. Dahlberg JE, Simon EH. Recombination in Newcastle disease virus (NDV): the problem of complementing heterozygotes. Virology 1969;38:490-493.
79. Dave VP, Allan JE, Slobod KS, et al. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells. Virology 1994;199:376-383.
80. de Breyne S, Monney RS, Curran J. Proteolytic processing and translation initiation: two independent mechanisms for the expression of the Sendai virus Y proteins. J Biol Chem 2004;279:16571-16580.
81. de Breyne S, Stalder R, Curran J. Intracellular processing of the Sendai virus C' protein leads to the generation of a Y protein module: structure-functional implications. FEBS Lett 2005;579:5685-5690.
82. de Leeuw OS, Hartog L, Koch G, et al. Effect of fusion protein cleavage site mutations on virulence of Newcastle disease virus: non-virulent cleavage site mutants revert to virulence after one passage in chicken brain. J Gen Virol 2003;84:475-484.
83. Delage G, Brochu P, Pelletier M, et al. Giant-cell pneumonia caused by parainfluenza virus. J Pediatr 1979;94:426-429.
84. Denny FW, Murphy TF, Clyde WA Jr, et al. Croup: an 11-year study in a pediatric practice. Pediatrics 1983;71:871-846.
85. Didcock L, Young DF, Goodbourn S, et al. Sendai virus and simian virus 5 block activation of interferon-responsive genes: importance for virus pathogenesis. J Virol 1999;73:3125-3133.
86. Didcock L, Young DF, Goodbourn S, et al. The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J Virol 1999;73:9928-9933.
87. DiNapoli JM, Nayak B, Yang L, et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 2010;84:1489-1503.
88. DiNapoli JM, Yang L, Samal SK, et al. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010;29:17-25.
89. do Carmo Debur M, Raboni SM, Flizikowski FB, et al. Immunohistochemical assessment of respiratory viruses in necropsy samples from lethal non-pandemic seasonal respiratory infections. J Clin Pathol 2010;63:930-934.
90. Dortmans JC, Koch G, Rottier PJ, Peeters BP. Virulence of pigeon paramyxovirus type 1 does not always correlate with the cleavability of its fusion protein. J Gen Virol 2009;90:2746-2750.
91. Dortmans JC, Rottier PJ, Koch G, et al. The viral replication complex is associated with the virulence of Newcastle disease virus. J Virol 2010;84:10113-10120.
92. Downham MA, Gardner PS, McQuillin J, et al. Role of respiratory viruses in childhood mortality. Br Med J 1975;1:235-239.
93. Doyle TM. A hitherto unrecorded disease of fowls due to a filter-passing virus. J Comp Pathol Therap 1927;40:144-169.
94. Drozd DR, Limaye AP, Moss RB, et al. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transpl Infect Dis 2012;0:1-5.
95. Durbin AP, Elkins WR, Murphy BR. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection. Vaccine 2000;18:2462-2469.
96. Durbin AP, McAuliffe JM, Collins PL, et al. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 1999;261:319-330.
97. Durbin AP, Siew JW, Murphy BR, et al. Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six. Virology 1997;234:74-83.
98. El Feghaly RE, McGann L, Bonville CA, et al. Local production of inflammatory mediators during childhood parainfluenza virus infection. Pediatr Infect Dis J 2010;29:e26-e31.
99. Elankumaran S, Chavan V, Qiao D, et al. Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J Virol 2010;84:3835-3844.
100. Elankumaran S, Rockemann D, Samal SK. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol 2006;80:7522-7534.
101. Estevez C, King D, Seal B, et al. Evaluation of Newcastle disease virus chimeras expressing the hemagglutinin-neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone. Virus Res 2007;129:182-190.
102. Fabian Z, Csatary CM, Szeberenyi J, et al. p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol 2007;81:2817-2830.
103. Fairchok MP, Martin ET, Kuypers J, et al. A prospective study of parainfluenza virus type 4 infections in children attending daycare. Pediatr Infect Dis J 2011;30:714-716.
104. Faisca P, Desmecht D. Sendai virus, the mouse parainfluenza type 1: a longstanding pathogen that remains up-to-date. Res Vet Sci 2007;82:115-125.
105. Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 1980;96:179-186.
106. Folkerts G, Verheyen AK, Geuens GM, et al. Virus-induced changes in airway responsiveness, morphology, and histamine levels in guinea pigs. Am Rev Respir Dis 1993;147:1569-1577.
107. Fox J, Hall C. Infections with other respiratory pathogens: influenza, parainfluenza, mumps and respiratory syncytial viruses; mycoplasma pneumoniae. In: Fox J, Hall C, eds. Viruses in Families. Littleton, MA: PSG Publishing Company; 1980:335-381.
108. Frank AL, Taber LH, Wells CR, et al. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis 1981;144:433-441.
109. Frank JA Jr, Warren RW, Tucker JA, et al. Disseminated parainfluenza infection in a child with severe combined immunodeficiency. Am J Dis Child 1983;137:1172-1174.
110. Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969;89:435-448.
111. Galinski MS, Troy RM, Banerjee AK. RNA editing in the phosphoprotein gene of the human parainfluenza virus type 3. Virology 1992;186:543-550.
112. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001;184:817-826.
113. Garcin D, Itoh M, Kolakofsky D. A point mutation in the Sendai virus accessory C proteins attenuates virulence for mice, but not virus growth in cell culture. Virology 1997;238:424-431.
114. Garcin D, Marq JB, Iseni F, et al. A short peptide at the amino terminus of the Sendai virus C protein acts as an independent element that induces STAT1 instability. J Virol 2004;78:8799-8811.
115. Garcin D, Marq JB, Strahle L, et al. All four Sendai virus C proteins bind Stat1, but only the larger forms also induce its mono-ubiquitination and degradation. Virology 2002;295:256-265.
116. Garcin D, Taylor G, Tanebayashi K, et al. The short Sendai virus leader region controls induction of programmed cell death. Virology 1998;243:340-353.
117. Ge J, Deng G, Wen Z, et al. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol 2007;81:150-158.
118. Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973;288:498-505.
119. Glezen W, Loda F, Denny F. Parainfluenza Viruses. In: Evans A, ed. Viral Infections of Humans: Epidemiology and Control. New York: Plenum Press; 1982:441-454.
120. Glezen WP. Reactive airway disorders in children. Role of respiratory virus infections. Clin Chest Med 1984;5:635-643.
121. Glezen WP, Frank AL, Taber LH, et al. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J Infect Dis 1984;150:851-857.
122. Goebel SJ, Taylor J, Barr BC, et al. Isolation of avian paramyxovirus 1 from a patient with a lethal case of pneumonia. J Virol 2007;81:12709-12714.
123. Goswami KK, Cameron KR, Russell WC, et al. Evidence for the persistence of paramyxoviruses in human bone marrows. J Gen Virol 1984;65:1881-1888.
124. Goswami KK, Randall RE, Lange LS, et al. Antibodies against the paramyxovirus SV5 in the cerebrospinal fluids of some multiple sclerosis patients. Nature 1987;327:244-247.
125. Gotoh B, Takeuchi K, Komatsu T, et al. The STAT2 activation process is a crucial target of Sendai virus C protein for the blockade of alpha interferon signaling. J Virol 2003;77:3360-3370.
126. Gotoh B, Takeuchi K, Komatsu T, et al. Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon-alpha/beta-mediated responses. FEBS Lett 1999;459:205-210.
127. Gould AR, Kattenbelt JA, Selleck P, et al. Virulent Newcastle disease in Australia: molecular epidemiological analysis of viruses isolated prior to and during the outbreaks of 1998-2000. Virus Res 2001;77:51-60.
128. Goyal SM, Drolet R, McPherson S, et al. Parainfluenza virus type 3 in pigs [letter]. Vet Rec 1986;119:363.
129. Granoff A. Studies on mixed infection with Newcastle disease virus. I. Isolation of Newcastle disease virus mutants and tests for genetic recombination between them. Virology 1959;9:636-648.
130. Granoff A. Studies on mixed infection with Newcastle disease virus. II. The occurrence of Newcastle disease virus heterozygotes and study of phenotypic mixing involving serotype and thermal stability. Virology 1959;9:649-670.
131. Greenberg DP, Walker RE, Lee MS, et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis 2005;191:1116-1122.
132. Griesenbach U, McLachlan G, Owaki T, et al. Validation of recombinant Sendai virus in a non-natural host model. Gene Ther 2011;18: 182-188.
133. Gross PA, Green RH, Curnen MG. Persistent infection with parainfluenza type 3 virus in man. Am Rev Respir Dis 1973;108:894-898.
134. Gurwitz D, Corey M, Levison H. Pulmonary function and bronchial reactivity in children after croup. Am Rev Respir Dis 1980;122:95-99.
135. Guzman-Suarez BB, Buckley MW, Gilmore ET, et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transpl Infect Dis 2012;14:427-433.
136. Hall CB, Douglas RG Jr, Simons RL, et al. Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. J Pediatr 1978;93:28-32.
137. Hall SL, Stokes A, Tierney EL, et al. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res 1992;22:173-184.
138. Hamaguchi M, Yoshida T, Nishikawa K, et al. Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are required to constitute an active complex. Virology 1983;128:105-117.
139. Han GZ, He CQ, Ding NZ, et al. Identification of a natural multi-recombinant of Newcastle disease virus. Virology 2008;371:54-60.
140. Hasan MK, Kato A, Muranaka M, et al. Versatility of the accessory C proteins of Sendai virus: contribution to virus assembly as an additional role. J Virol 2000;74:5619-5628.
141. Hasman H, Pachucki CT, Unal A, et al. Aetiology of influenza-like illness in adults includes parainfluenzavirus type 4. J Med Microbiol 2009;58:408-413.
142. He B, Lamb RA. Effect of inserting paramyxovirus simian virus 5 gene junctions at the HN/L gene junction: analysis of accumulation of mRNAs transcribed from rescued viable viruses. J Virol 1999;73:6228-6234.
143. He B, Leser GP, Paterson RG, et al. The paramyxovirus SV5 small hydrophobic (SH) protein is not essential for virus growth in tissue culture cells. Virology 1998;250:30-40.
144. He B, Paterson RG, Stock N, et al. Recovery of paramyxovirus simian virus 5 with a V protein lacking the conserved cysteine-rich domain: the multifunctional V protein blocks both interferon-beta induction and interferon signaling. Virology 2002;303:15-32.
145. He CQ, Ding NZ, Han GZ, et al. Natural recombination between Newcastle disease virus vaccine strains and circulating viruses. J Virol 2008.
146. Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 1999;340:260-264.
147. Heinen E, Herbst W, Schmeer N. Isolation of a cytopathogenic virus from a case of porcine reproductive and respiratory syndrome (PRRS) and its characterization as parainfluenza virus type 2. Arch Virol 1998;143:2233-2239.
148. Henrickson KJ, Kingsbury DW, van Wyke Coelingh KL, et al. Neutralizing epitopes of human parainfluenza virus type 3 are conformational and cannot be imitated by synthetic peptides. Vaccine 1991;9:243-249.
149. Henrickson KJ, Kuhn SM, Savatski LL. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin Infect Dis 1994;18:770-779.
150. Henrickson KJ, Savatski LL. Antigenic structure, function, and evolution of the hemagglutinin-neuraminidase protein of human parainfluenza virus type 1. J Infect Dis 1997;176:867-875.
151. Hetherington SV, Watson AS, Scroggs RA, et al. Human parainfluenza virus type 1 evolution combines cocirculation of strains and development of geographically restricted lineages. J Infect Dis 1994;169:248-252.
152. Homann HE, Hofschneider PH, Neubert WJ. Sendai virus gene expression in lytically and persistently infected cells. Virology 1990;177:131-140.
153. Horikami SM, Curran J, Kolakofsky D, et al. Complexes of Sendai virus NP-P and P-L proteins are required for defective interfering particle genome replication in vitro. J Virol 1992;66:4901-4908.
154. Horikami SM, Hector RE, Smallwood S, et al. The Sendai virus C protein binds the L polymerase protein to inhibit viral RNA synthesis. Virology 1997;235:261-270.
155. Horikami SM, Smallwood S, Moyer SA. The Sendai virus V protein interacts with the NP protein to regulate viral genome RNA replication. Virology 1996;222:383-390.
156. Horwood PF, Gravel JL, Mahony TJ. Identification of two distinct bovine parainfluenza virus type 3 genotypes. J Gen Virol 2008;89:1643-1648.
157. Hosaka Y, Watabe T. Cryoelectron microscopy of vitrified Sendai virions. J Virol Methods 1988;22:347-349.
158. Hotez PJ, Goldstein B, Ziegler J, et al. Adult respiratory distress syndrome associated with parainfluenza virus type 1 in children. Pediatr Infect Dis J 1990;9:750-752.
159. Hou S, Doherty PC, Zijlstra M, et al. Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells. J Immunol 1992;149:1319-1325.
160. Howe C, Morgan C, de Vaux St. Cyr C, et al. Morphogenesis of type 2 parainfluenza virus examined by light and electron microscopy. J Virol 1967;1:215-237.
161. Hsiung GD. Parainfluenza-5 virus. Infection of man and animal. Prog Med Virol 1972;14:241-274.
162. Hsu M, Choppin PW. Analysis of Sendai virus mRNAs with cDNA clones of viral genes and sequences of biologically important regions of the fusion protein. Proc Natl Acad Sci U S A 1984;81:7732-7736.
163. Hu CJ, Kato A, Bowman MC, et al. Role of primary constitutive phosphorylation of Sendai virus P and V proteins in viral replication and pathogenesis. Virology 1999;263:195-208.
164. Huang Z, Elankumaran S, Yunus AS, et al. A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J Virol 2004;78:10054-10063.
165. Huang Z, Krishnamurthy S, Panda A, et al. Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J Virol 2003;77:8676-8685.
166. Huang Z, Panda A, Elankumaran S, et al. The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. J Virol 2004;78:4176-4184.
167. Hull RN, Minner JR, Smith JW. New viral agents recovered from tissue cultures of monkey kidney cells. I. Origin and properties of cytopathogenic agents S.V.1, S.V.2, S.V.4, S.V.5, S.V.6, S.V.11, S.V.12 and S.V.15. Am J Hyg 1956;63:204-215.
168. Hurwitz JL. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections. Pediatr Infect Dis J 2008;27:S126-S128.
169. Irie T, Nagata N, Yoshida T, et al. Paramyxovirus Sendai virus C proteins are essential for maintenance of negative-sense RNA genome in virus particles. Virology 2008;374:495-505.
170. Iseni F, Garcin D, Nishio M, et al. Sendai virus trailer RNA binds TIAR, a cellular protein involved in virus-induced apoptosis. EMBO J 2002;21:5141-5150.
171. Ito Y, Tsurudome M, Hishiyama M, et al. Immunological interrelationships among human and non-human paramyxoviruses revealed by immunoprecipitation. J Gen Virol 1987;68(Pt 5):1289-1297.
172. Iverson LE, Rose JK. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 1981;23:477-484.
173. Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004;113:1758-1764.
174. Iwata S, Schmidt AC, Titani K, et al. Assignment of disulfide bridges in the fusion glycoprotein of Sendai virus. J Virol 1994;68:3200-3206.
175. Jarvis WR, Middleton PJ, Gelfand EW. Parainfluenza pneumonia in severe combined immunodeficiency disease. J Pediatr 1979;94:423-425.
176. Jeon WJ, Lee EK, Kwon JH, et al. Full-length genome sequence of avian paramyxovirus type 4 isolated from a mallard duck. Virus Genes 2008;37:342-350.
177. Johnson DP, Green RH. Viremia during parainfluenza type 3 virus infection of hamsters. Proc Soc Exp Biol Med 1973;144:745-748.
178. Johnson DW, Jacobson S, Edney PC, et al. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. N Engl J Med 1998;339:498-503.
179. Johnson K, Chanock R, Cook M, et al. Studies of a new human hemadsorption virus. I. Isolation, properties and characterization. Am J Hyg 1960;71:81.
180. Kaneda Y. A non-replicating oncolytic vector as a novel therapeutic tool against cancer. BMB Rep 2010;43:773-780.
181. Kapikian A, Chanock R, Reichelderfer T, et al. Inoculation of human volunteers with parainfluenza virus type 3. JAMA 1961;183:537-541.
182. Karron RA, Belshe RB, Wright PF, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003;22:394-405.
183. Karron RA, Casey R, Thumar B, et al. The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children. Pediatr Infect Dis J 2011;30:e186-e191.
184. Karron RA, Makhene M, Gay K, et al. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two-to six-month-old infants. Pediatr Infect Dis J 1996;15:650-654.
185. Karron RA, O'Brien KL, Froehlich JL, et al. Molecular epidemiology of a parainfluenza type 3 virus outbreak on a pediatric ward. J Infect Dis 1993;167:1441-1445.
186. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005;191:1093-1104.
187. Karron RA, Wright PF, Hall SL, et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995;171:1107-1114.
188. Karron RA, Wright PF, Newman FK, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995;172:1445-1450.
189. Kasel JA, Frank AL, Keitel WA, et al. Acquisition of serum antibodies to specific viral glycoproteins of parainfluenza virus 3 in children. J Virol 1984;52:828-832.
190. Kast WM, Bronkhorst AM, de Waal LP, et al. Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations. J Exp Med 1986;164:723-738.
191. Kast WM, Roux L, Curren J, et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A 1991;88:2283-2287.
192. Kato A, Kiyotani K, Hasan MK, et al. Sendai virus gene start signals are not equivalent in reinitiation capacity: moderation at the fusion protein gene. J Virol 1999;73:9237-9246.
193. Kato A, Kiyotani K, Sakai Y, et al. The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J 1997;16:578-587.
194. Kato A, Kiyotani K, Sakai Y, et al. Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis. J Virol 1997;71:7266-7272.
195. Kattenbelt JA, Stevens MP, Gould AR. Sequence variation in the Newcastle disease virus genome. Virus Res 2006;116:168-184.
196. Kawano M, Tsurudome M, Oki N, et al. Sequence determination of the P gene of simian virus 41: presence of irregular deletions near the RNA-editing sites of paramyxoviruses. J Gen Virol 1993;74(Pt 5):911-916.
197. Kim H-W, Vargosko A, Chanock R, et al. Parainfluenza 2 virus etiologic association with croup. Pediatrics 1961;28:614-621.
198. Kim HW, Arrobio JO, Brandt CD, et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol 1973;98:216-225.
199. Kim HW, Brandt CD, Arrobio JO, et al. Influenza A and B virus infection in infants and young children during the years 1957-1976. Am J Epidemiol 1979;109:464-479.
200. King JC Jr, Burke AR, Clemens JD, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 1993;12:733-739.
201. Knott AM, Long CE, Hall CB. Parainfluenza viral infections in pediatric outpatients: seasonal patterns and clinical characteristics. Pediatr Infect Dis J 1994;13:269-273.
202. Kohama T, Garten W, Klenk HD. Changes in conformation and charge paralleling proteolytic activation of Newcastle disease virus glycoproteins. Virology 1981;111:364-376.
203. Kolakofsky D, Le Mercier P, Iseni F, et al. Viral DNA polymerase scanning and the gymnastics of Sendai virus RNA synthesis. Virology 2004;318:463-473.
204. Kolakofsky D, Pelet T, Garcin D, et al. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol 1998;72:891-899.
205. Kolakofsky D, Roux L, Garcin D, et al. Paramyxovirus mRNA editing, the "rule of six" and error catastrophe: a hypothesis. J Gen Virol 2005;86:1869-1877.
206. Komada H, Bando H, Ito M, et al. Sequence analyses of human parainfluenza virus type 4A and type 4B fusion proteins. J Gen Virol 1995;76(Pt 12):3205-3210.
207. Komada H, Klippmark E, Orvell C, et al. Immunological relationships between parainfluenza virus type 4 and other paramyxoviruses studied by use of monoclonal antibodies. Arch Virol 1991;116:277-283.
208. Komada H, Tsurudome M, Ueda M, et al. Isolation and characterization of monoclonal antibodies to human parainfluenza virus type 4 and their use in revealing antigenic relation between subtypes 4A and 4B. Virology 1989;171:28-37.
209. Komatsu T, Takeuchi K, Gotoh B. Bovine parainfluenza virus type 3 accessory proteins that suppress beta interferon production. Microbes Infect 2007;9:954-962.
210. Komatsu T, Takeuchi K, Yokoo J, et al. C and V proteins of Sendai virus target signaling pathways leading to IRF-3 activation for the negative regulation of interferon-beta production. Virology 2004;325: 137-148.
211. Komatsu T, Takeuchi K, Yokoo J, et al. Sendai virus C protein impairs both phosphorylation and dephosphorylation processes of Stat1. FEBS Lett 2002;511:139-144.
212. Kondo K, Bando H, Tsurudome M, et al. Sequence analysis of the phosphoprotein (P) genes of human parainfluenza type 4A and 4B viruses and RNA editing at transcript of the P genes: the number of G residues added is imprecise. Virology 1990;178:321-326.
213. Koyama AH, Irie H, Kato A, et al. Virus multiplication and induction of apoptosis by Sendai virus: role of the C proteins. Microbes Infect 2003;5:373-378.
214. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 1987;196:947-950.
215. Kozak M. Initiation of translation in prokaryotes and eukaryotes. Gene 1999;234:187-208.
216. Kumar S, Collins PL, Samal SK. Identification of simian agent 10 as human parainfluenza virus type 3 suggests transmission of a human virus to an African monkey. J Virol 2010;84:13068-13070.
217. Kumar S, Nayak B, Collins PL, et al. Complete genome sequence of avian paramyxovirus type 3 reveals an unusually long trailer region. Virus Res 2008;137:189-197.
218. Kumar S, Nayak B, Samuel AS, et al. Complete genome sequence of avian paramyxovirus-3 strain Wisconsin: evidence for the existence of subgroups within the serotype. Virus Res 2010;149:78-85.
219. Kurotani A, Kiyotani K, Kato A, et al. Sendai virus C proteins are categorically nonessential gene products but silencing their expression severely impairs viral replication and pathogenesis. Genes Cells 1998;3:111-124.
220. Kuroya N, Ishida M. Newborn virus pneumonitis (type Sendai): II. Isolation of new virus possessing hemagglutinin activity. Yokohama Med Bull 1953;4:217-233.
221. Kusagawa S, Komada H, Mao X, et al. Antigenic and molecular properties of Murayama virus isolated from cynomolgus monkeys: the virus is closely related to avian paramyxovirus type 2. Virology 1993;194:828-832.
222. Lamb RA, Collins PL, Kolakofsky D. et al. Paramyxoviridae. In: Fauquet MA, Mayo J, Maniloff J, Desselberger U, Ball LA, eds. Eighth Report of the International Committee on Taxonomy of Viruses. London: Elsevier/Academic Press; 2005:655-668.
223. Lamb RA, Mahy BW, Choppin PW. The synthesis of Sendai virus polypeptides in infected cells. Virology 1976;69:116-131.
224. Latorre P, Cadd T, Itoh M, et al. The various Sendai virus C proteins are not functionally equivalent and exert both positive and negative effects on viral RNA accumulation during the course of infection. J Virol 1998;72:5984-5993.
225. Latorre P, Kolakofsky D, Curran J. Sendai virus Y proteins are initiated by a ribosomal shunt. Mol Cell Biol 1998;18:5021-5031.
226. Lawrence MC, Borg NA, Streltsov VA, et al. Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. J Mol Biol 2004;335:1343-1357.
227. Lee MS, Walker RE, Mendelman PM. Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials. Hum Vaccin 2005;1:6-11.
228. Lee SH, Boutilier JE, MacDonald MA, et al. Enhanced detection of respiratory viruses using the shell vial technique and monoclonal antibodies. J Virol Methods 1992;39:39-46.
229. Lehman DJ, Roof LL, Brideau RJ, et al. Comparison of soluble and secreted forms of human parainfluenza virus type 3 glycoproteins expressed from mammalian and insect cells as subunit vaccines. J Gen Virol 1993;74:459-469.
230. Lemen RJ, Quan SF, Witten ML, et al. Canine parainfluenza type 2 bronchiolitis increases histamine responsiveness in beagle puppies. Am Rev Respir Dis 1990;141:199-207.
231. Li T, Chen X, Garbutt KC, et al. Structure of DDB1 in complex with a paramyxovirus V protein: viral hijack of a propeller cluster in ubiquitin ligase. Cell 2006;124:105-117.
232. Lin GY, Lamb RA. The paramyxovirus simian virus 5 V protein slows progression of the cell cycle. J Virol 2000;74:9152-166.
233. Lin Y, Bright AC, Rothermel TA, et al. Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene. J Virol 2003;77:3371-3383.
234. Lin Y, Horvath F, Aligo JA, et al. The role of simian virus 5 V protein on viral RNA synthesis. Virology 2005;338:270-280.
235. Lipkind M, Shoham D, Shihmanter E. Isolation of a paramyxovirus from pigs in Israel and its antigenic relationships with avian paramyxoviruses. J Gen Virol 1986;67(Pt 3):427-439.
236. Liston P, Briedis DJ. Ribosomal frameshifting during translation of measles virus P protein mRNA is capable of directing synthesis of a unique protein. J Virol 1995;69:6742-6750.
237. Loney C, Mottet-Osman G, Roux L, et al. 2009. Paramyxovirus ultrastructure and genome packaging: cryo-electron tomography of Sendai virus. J Virol 83:8191-8197.
238. Loughlin GM, Taussig LM. Pulmonary function in children with a history of laryngotracheobronchitis. J Pediatr 1979;94:365-369.
239. Lu LL, Puri M, Horvath CM, et al. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1. J Biol Chem 2008;283:14269-14276.
240. Lucas JR, Haas EA, Masoumi H, et al. Sudden death in a toddler with laryngotracheitis caused by human parainfluenza virus-1. Pediatr Dev Pathol 2009;12:165-168.
241. Ludwig K, Schade B, Bottcher C, et al. Electron cryomicroscopy reveals different F1+F2 protein States in intact parainfluenza virions. J Virol 2008;82:3775-3781.
242. Madansky CH, Bratt MA. Noncytopathic mutants of Newcastle disease virus are defective in virus-specific RNA synthesis. J Virol 1981;37:317-327.
243. Madhi SA, Ramasamy N, Petersen K, et al. Severe lower respiratory tract infections associated with human parainfluenza viruses 1-3 in children infected and noninfected with HIV type 1. Eur J Clin Microbiol Infect Dis 2002;21:499-505.
244. Malur AG, Chattopadhyay S, Maitra RK, et al. Inhibition of STAT 1 phosphorylation by human parainfluenza virus type 3 C protein. J Virol 2005;79:7877-7882.
245. Malur AG, Hoffman MA, Banerjee AK. The human parainfluenza virus type 3 (hPIV 3) C protein inhibits viral transcription. Virus Res 2004;99:199-204.
246. Mao H, Thakur CS, Chattopadhyay S, et al. Inhibition of human parainfluenza virus type 3 infection by novel small molecules. Antiviral Res 2008;77:83-94.
247. Marx A, Gary HE Jr, Marston BJ, et al. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. Clin Infect Dis 1999;29:134-140.
248. Marx A, Torok TJ, Holman RC, et al. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis 1997;176:1423-1427.
249. Matsuoka Y, Curran J, Pelet T, et al. The P gene of human parainfluenza virus type 1 encodes P and C proteins but not a cysteine-rich V protein. J Virol 1991;65:3406-3410.
250. Mazanec MB, Lamm ME, Lyn D, et al. Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. Virus Res 1992;23:1-12.
251. Merson JR, Hull RA, Estes MK, et al. Molecular cloning and sequence determination of the fusion protein gene of human parainfluenza virus type 1. Virology 1988;167:97-105.
252. Merz DC, Prehm P, Scheid A, et al. Inhibition of the neuraminidase of paramyxoviruses by halide ions: a possible means of modulating the two activities of the HN protein. Virology 1981;112:296-305.
253. Millar NS, Chambers P, Emmerson PT. Nucleotide sequence of the fusion and haemagglutinin-neuraminidase glycoprotein genes of Newcastle disease virus, strain Ulster: molecular basis for variations in pathogenicity between strains. J Gen Virol 1988;69:613-620.
254. Miller PJ, Afonso CL, Spackman E, et al. Evidence for a new avian paramyxovirus serotype 10 detected in rockhopper penguins from the Falkland Islands. J Virol 2010;84:11496-504.
255. Miller RH, Pursell AR, Mitchell FE, et al. A newly discovered myxovirus (S.V.41) isolated from cell cultures of cynomolgus monkey kidney. Am J Hyg 1964;80:365-376.
256. Miyairi I, DeVincenzo JP. Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev 2008;21:686-703.
257. Morgan C, Howe C. Structure and development of viruses as observed in the electron microscope. IX. Entry of parainfluenza I (Sendai) virus. J Virol 1968;2:1122-1132.
258. Morrison T, McQuain C, Sergel T, et al. The role of the amino terminus of F1 of the Newcastle disease virus fusion protein in cleavage and fusion. Virology 1993;193:997-1000.
259. Moscona A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest 2005;115:1688-1698.
260. Moscona A, Peluso RW. Fusion properties of cells persistently infected with human parainfluenza virus type 3: participation of hemagglutinin-neuraminidase in membrane fusion. J Virol 1991;65:2773-2777.
261. Moscona A, Peluso RW. Persistent infection with human parainfluenza virus 3 in CV-1 cells: analysis of the role of defective interfering particles. Virology 1993;194:399-402.
262. Moscona A, Porotto M, Palmer S, et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis 2010;202:234-241.
263. Mufson MA, Levine HD, Wasil RE, et al. Epidemiology of respiratory syncytial virus infection among infants and children in Chicago. Am J Epidemiol 1973;98:88-95.
264. Murphy BR, Prince GA, Collins PL, et al. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res 1988;11:1-15.
265. Murphy BR, Richman DD, Chalhub EG, et al. Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect Immun 1975;12:62-68.
266. Nagai Y. Virus activation by host proteinases. A pivotal role in the spread of infection, tissue tropism and pathogenicity. Microbiol Immunol 1995;39:1-9.
267. Nagai Y, Klenk HD. Activation of precursors to both glycoporteins of Newcastle disease virus by proteolytic cleavage. Virology 1977;77:125-134.
268. Nagai Y, Takakura A, Irie T, et al. Sendai virus: Evolution from mouse pathogen to state-of-the-art tool in virus research and biotechnology. In: Samal SK, ed. The Biology of Paramyoviruses. Norwich, UK: Caister Academic Press; 2011:115-173.
269. Nayak B, Kumar S, Collins PL, et al. Molecular characterization and complete genome sequence of avian paramyxovirus type 4 prototype strain duck/Hong Kong/D3/75. Virol J 2008;5:124.
270. Nayak B, Rout SN, Kumar S, et al. Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS One 2009;4:e6509.
271. Newman JT, Riggs JM, Surman SR, et al. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses. J Virol 2004;78:2017-2028.
272. Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001;98:573-578.
273. Nichols WG, Erdman DD, Han A, et al. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biol Blood Marrow Transplant 2004;10:58-64.
274. Nishio M, Ohtsuka J, Tsurudome M, et al. Human parainfluenza virus type 2 V protein inhibits genome replication by binding to the L protein: possible role in promoting viral fitness. J Virol 2008;82:6130-6138.
275. Nishio M, Tsurudome M, Bando H, et al. Immunological relationships of simian virus 41 (SV41) to other paramyxoviruses and serological evidence of SV41 infection in human populations. J Gen Virol 1990;71:2093-2097.
276. Nishio M, Tsurudome M, Ito M, et al. Identification of paramyxovirus V protein residues essential for STAT protein degradation and promotion of virus replication. J Virol 2005;79:8591-8601.
277. Nishio M, Tsurudome M, Ito M, et al. Human parainfluenza virus type 4 is incapable of evading the interferon-induced antiviral effect. J Virol 2005;79:14756-14768.
278. Nolan SM, Skiadopoulos MH, Bradley K, et al. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates. Vaccine 2007;25:6409-6422.
279. Ogino T, Kobayashi M, Iwama M, et al. Sendai virus RNA-dependent RNA polymerase L protein catalyzes cap methylation of virus-specific mRNA. J Biol Chem 2005;280:4429-4435.
280. Ohgimoto S, Bando H, Kawano M, et al. Sequence analysis of P gene of human parainfluenza type 2 virus: P and cysteine-rich proteins are translated by two mRNAs that differ by two nontemplated G residues. Virology 1990;177:116-123.
281. Okada H, Seto JT, McQueen NL, et al. Determinants of pantropism of the F1-R mutant of Sendai virus: specific mutations involved are in the F and M genes. Arch Virol 1998;143:2343-2352.
282. Orvell C, Grandien M. The effects of monoclonal antibodies on biologic activities of structural proteins of Sendai virus. J Immunol 1982;129:2779-2787.
283. Panda A, Huang Z, Elankumaran S, et al. Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb Pathog 2004;36:1-10.
284. Park MS, Steel J, Garcia-Sastre A, et al. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A 2006;103:8203-8208.
285. Parker JC, Reynolds RK. Natural history of Sendai virus infection in mice. Am J Epidemiol 1968;88:112-125.
286. Parrott R, Vargosko A, KIMHW, et al. Acute respiratory diseases of viral etiology. III. Parainfluenza. Myxoviruses. Am J Public Health 1962;52:907-917.
287. Parrott RH, Vargosko A, Luckey A, et al. Clinical features of infection with hemadsorption viruses. N Engl J Med 1959;260:731-738.
288. Paterson RG, Leser GP, Shaughnessy MA, et al. The paramyxovirus SV5 V protein binds two atoms of zinc and is a structural component of virions. Virology 1995;208:121-131.
289. Peeters BP, de Leeuw OS, Koch G, et al. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 1999;73:5001-5009.
290. Pelet T, Curran J, Kolakofsky D. The P gene of bovine parainfluenza virus 3 expresses all three reading frames from a single mRNA editing site. Embo J 1991;10:443-448.
291. Poch O, Blumberg BM, Bougueleret L, et al. Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains. J Gen Virol 1990;71:1153-1162.
292. Poch O, Sauvaget I, Delarue M, et al. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. Embo J 1989;8:3867-3874.
293. Poole E, He B, Lamb RA, et al. The V proteins of simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology 2002;303:33-46.
294. Porotto M, Fornabaio M, Kellogg GE, et al. A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism. J Virol 2007;81:3216-3228.
295. Porotto M, Greengard O, Poltoratskaia N, et al. Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a neuraminidase-deficient variant. J Virol 2001;75:7481-7488.
296. Porotto M, Murrell M, Greengard O, et al. Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion. J Virol 2003;77:3647-3654.
297. Porotto M, Yokoyama CC, Palermo LM, et al. Viral entry inhibitors targeted to the membrane site of action. J Virol 2010;84:6760-6768.
298. Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985;55:517-520.
299. Pringle CR. The genetics of vesiculoviruses. Arch Virol 1982;72:1-34.
300. Puhler F, Willuda J, Puhlmann J, et al. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Gene Ther 2008;15:371-383.
301. Qiao D, Janke BH, Elankumaran S. Complete genome sequence and pathogenicity of two swine parainfluenzavirus 3 isolates from pigs in the United States. J Virol 2010;84:686-694.
302. Qin Z, Sun L, Ma B, et al. F gene recombination between genotype II and VII Newcastle disease virus. Virus Res 2008;131:299-303.
303. Ramachandran A, Horvath CM. Dissociation of paramyxovirus interferon evasion activities: universal and virus-specific requirements for conserved V protein amino acids in MDA5 interference. J Virol 2010;84:11152-11163.
304. Rassa JC, Parks GD. Molecular basis for naturally occurring elevated readthrough transcription across the M-F junction of the paramyxovirus SV5. Virology 1998;247:274-286.
305. Ray R, Duncan J, Quinn R, et al. Distinct hemagglutinin and neuraminidase epitopes involved in antigenic variation of recent human parainfluenza virus type 2 isolates. Virus Res 1992;24:107-113.
306. Ray R, Glaze BJ, Compans RW. Role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response. J Virol 1988;62:783-787.
307. Ray R, Glaze BJ, Moldoveanu Z, et al. Intranasal immunization of hamsters with envelope glycoproteins of human parainfluenza virus type 3. J Infect Dis 1988;157:648-654.
308. Re GG. Deletion mutants of paramyxoviruses. In: Kingsbury DW, ed. The Paramyxoviruses. New York: Plenum Press; 1991:275-298.
309. Reed G, Jewett PH, Thompson J, et al. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis 1997;175:807-813.
310. Ren L, Gonzalez R, Xie Z, et al. Human parainfluenza virus type 4 infection in Chinese children with lower respiratory tract infections: a comparison study. J Clin Virol 2011;51:209-212.
311. Rochat S, Komada H, Kolakofsky D. Loss of V protein expression in human parainfluenza virus type 1 is not a recent event. Virus Res 1992;24:137-144.
312. Rockwell NC, Krysan DJ, Komiyama T, et al. Precursor processing by kex2/furin proteases. Chem Rev 2002;102:4525-4548.
313. Romer-Oberdorfer A, Werner O, Veits J, et al. Contribution of the length of the HN protein and the sequence of the F protein cleavage site to Newcastle disease virus pathogenicity. J Gen Virol 2003;84:3121-3129.
314. Rout SN, Samal SK. The large polymerase protein is associated with the virulence of Newcastle disease virus. J Virol 2008;82:7828-7836.
315. Russell CJ, Jardetzky TS, Lamb RA. Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO J 2001;20:4024-4034.
316. Ryan C, Zaitsev V, Tindal DJ, et al. Structural analysis of a designed inhibitor complexed with the hemagglutinin-neuraminidase of Newcastle disease virus. Glycoconj J 2006;23:135-141.
317. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4:406-425.
318. Sakaguchi T, Kato A, Kiyotani K, et al. Studies on the paramyxovirus accessory genes by reverse genetics in the Sendai virus-mouse system. Proc Jpn Acad Ser B Phys Biol Sci 2008;84:439-451.
319. Sakaguchi T, Kato A, Sugahara F, et al. AIP1/Alix is a binding partner of Sendai virus C protein and facilitates virus budding. J Virol 2005;79:8933-8941.
320. Sakaguchi T, Toyoda T, Gotoh B, et al. Newcastle disease virus evolution. I. Multiple lineages defined by sequence variability of the hemagglutinin-neuraminidase gene. Virology 1989;169:260-272.
321. Samal SK. Newcastle disease and related avian paramyxoviruses. In: Samal SK, ed. The Biology of Paramyxoviruses. Norwich, UK: Caister Academic Press; 2011.
322. Samuel AS, Kumar S, Madhuri S, et al. Complete sequence of the genome of avian paramyxovirus type 9 and comparison with other paramyxoviruses. Virus Res 2009;142:10-18.
323. Samuel AS, Paldurai A, Kumar S, et al. Complete genome sequence of avian paramyxovirus (APMV) serotype 5 completes the analysis of nine APMV serotypes and reveals the longest APMV genome. PLoS One 2010;5:e9269.
324. Schaap-Nutt A, D'Angelo C, Amaro-Carambot E, et al. Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates. Virology 2010;406:65-79.
325. Schaap-Nutt A, D'Angelo C, Scull MA, et al. Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates. Virology 2010;397:285-298.
326. Schaap-Nutt A, Higgins C, Amaro-Carambot E, et al. Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates. J Virol 2011;85:4007-4019.
327. Schaap-Nutt A, Scull MA, Schmidt AC, et al. Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys. Vaccine 2010;28:2788-2798.
328. Scheid A. Paramyxoviridae. In: Nermut MV, Steven AC, eds. Animal Virus Structure. New York: Elsevier; 1987:233-252.
329. Schmidt AC, McAuliffe JM, Huang A, et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 2000;74:8922-8929.
330. Schmitt AP, Leser GP, Morita E, et al. Evidence for a new viral late-domain core sequence, FPIV, necessary for budding of a paramyxovirus. J Virol 2005;79:2988-2997.
331. Schomacker H, Hebner RM, Boonyaratanakornkit J, et al. The C proteins of human parainfluenza virus type I block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome. PLoS One 2012;7:e28382.
332. Segal AO, Crighton EJ, Moineddin R, et al. Croup hospitalizations in Ontario: a 14-year time-series analysis. Pediatrics 2005;116:51-55.
333. Servan de Almeida R, Maminiaina OF, Gil P, et al. Africa, a reservoir of new virulent strains of Newcastle disease virus? Vaccine 2009;27:3127-3129.
334. Shengqing Y, Kishida N, Ito H, et al. Generation of velogenic Newcastle disease viruses from a nonpathogenic waterfowl isolate by passaging in chickens. Virology 2002;301:206-211.
335. Siber GR, Leombruno D, Leszczynski J, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 1994;169:1368-1373.
336. Singh-Naz N, Willy M, Riggs N. Outbreak of parainfluenza virus type 3 in a neonatal nursery. Pediatr Infect Dis J 1990;9:31-33.
337. Skiadopoulos MH, Durbin AP, Tatem JM, et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol 1998;72:1762-1768.
338. Skiadopoulos MH, Schmidt AC, Riggs JM, et al. Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic. J Virol 2003;77:1141-1148.
339. Skiadopoulos MH, Surman S, Tatem JM, et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 1999;73:1374-1381.
340. Skiadopoulos MH, Surman SR, Riggs JM, et al. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology 2002;297:153-160.
341. Skiadopoulos MH, Surman SR, Riggs JM, et al. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology 2002;297:136-152.
342. Skiadopoulos MH, Vogel L, Riggs JM, et al. The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations. J Virol 2003;77:270-279.
343. Slavin KA, Passaro DJ, Hacker JK, et al. Parainfluenza virus type 4: case report and review of the literature. Pediatr Infect Dis J 2000;19:893-896.
344. Slobod KS, Shenep JL, Lujan-Zilbermann J, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004;22:3182-3186.
345. Smith CB, Purcell RH, Bellanti JA, et al. Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med 1966;275:1145-1152.
346. Song Q, Cao Y, Li Q, et al. Artificial recombination may influence the evolutionary analysis of Newcastle disease virus. J Virol 2011;85:10409-10414.
347. Southern JA, Precious B, Randall RE. Two nontemplated nucleotide additions are required to generate the P mRNA of parainfluenza virus type 2 since the RNA genome encodes protein V. Virology 1990;177:388-390.
348. Spann KM, Collins PL, Teng MN. Genetic recombination during coinfection of two mutants of human respiratory syncytial virus. J Virol 2003;77:11201-11211.
349. Spriggs MK, Collins PL. Human parainfluenza virus type 3: messenger RNAs, polypeptide coding assignments, intergenic sequences, and genetic map. J Virol 1986;59:646-654.
350. Spriggs MK, Murphy BR, Prince GA, et al. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol 1987;61:3416-3423.
351. Spriggs MK, Olmsted RA, Venkatesan S, et al. Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses. Virology 1986;152:241-251.
352. Steward M, Samson AC, Errington W, et al. The Newcastle disease virus V protein binds zinc. Arch Virol 1995;140:1321-1328.
353. Steward M, Vipond IB, Millar NS, et al. RNA editing in Newcastle disease virus. J Gen Virol 1993;74:2539-2547.
354. Strahle L, Garcin D, Kolakofsky D. Sendai virus defective-interfering genomes and the activation of interferon-beta. Virology 2006;351:101-111.
355. Strahle L, Marq JB, Brini A, et al. Activation of the beta interferon promoter by unnatural Sendai virus infection requires RIG-I and is inhibited by viral C proteins. J Virol 2007;81:12227-12237.
356. Subbiah M, Khattar SK, Collins PL, et al. Mutations in the fusion protein cleavage site of avian paramyxovirus serotype 2 that increase cleavability and syncytia formation but do not increase viral virulence in chickens. J Virol 2011;85:5394-5405.
357. Subbiah M, Nayak S, Collins PL, et al. Complete genome sequences of avian paramyxovirus serotype 2 (APMV-2) strains Bangor, England and Kenya: evidence for the existence of subgroups within serotype 2. Virus Res 2010;152:85-95.
358. Subbiah M, Xiao S, Collins PL, et al. Complete sequence of the genome of avian paramyxovirus type 2 (strain Yucaipa) and comparison with other paramyxoviruses. Virus Res 2008;137:40-48.
359. Sugahara F, Uchiyama T, Watanabe H, et al. Paramyxovirus Sendai virus-like particle formation by expression of multiple viral proteins and acceleration of its release by C protein. Virology 2004;325:1-10.
360. Sun M, Rothermel TA, Shuman L, et al. Conserved cysteine-rich domain of paramyxovirus simian virus 5 V protein plays an important role in blocking apoptosis. J Virol 2004;78:5068-5078.
361. Suzuki T, Portner A, Scroggs RA, et al. Receptor specificities of human respiroviruses. J Virol 2001;75:4604-4613.
362. Swanson K, Wen X, Leser GP, et al. Structure of the Newcastle disease virus F protein in the post-fusion conformation. Virology 2010;402:372-379.
363. Takeuchi K, Komatsu T, Kitagawa Y, et al. Sendai virus C protein plays a role in restricting PKR activation by limiting the generation of intracellular double-stranded RNA. J Virol 2008;82:10102-10110.
364. Takeuchi K, Komatsu T, Yokoo J, et al. Sendai virus C protein physically associates with Stat1. Genes Cells 2001;6:545-557.
365. Takimoto T, Portner A. Molecular mechanism of paramyxovirus budding. Virus Res 2004;106:133-145.
366. Tamura K, Dudley J, Nei M, et al. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596-1599.
367. Tan LT, Xu HY, Wang YL, et al. Molecular characterization of three new virulent Newcastle disease virus variants isolated in China. J Clin Microbiol 2008;46:750-753.
368. Tao T, Davoodi F, Cho CJ, et al. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine 2000;18:1359-1366.
369. Tapparel C, Hausmann S, Pelet T, et al. Inhibition of Sendai virus genome replication due to promoter-increased selectivity: a possible role for the accessory C proteins. J Virol 1997;71:9588-9599.
370. Tapparel C, Maurice D, Roux L. The activity of Sendai virus genomic and antigenomic promoters requires a second element past the leader template regions: a motif (GNNNNN)3 is essential for replication. J Virol 1998;72:3117-3128.
371. Tarbouriech N, Curran J, Ruigrok RW, et al. Tetrameric coiled coil domain of Sendai virus phosphoprotein. Nat Struct Biol 2000;7:777-781.
372. Tashiro M, Seto JT, Choosakul S, et al. Changes in specific cleavability of the Sendai virus fusion protein: implications for pathogenicity in mice. J Gen Virol 1992;73:1575-1579.
373. Tashiro M, Yamakawa M, Tobita K, et al. Organ tropism of Sendai virus in mice: proteolytic activation of the fusion glycoprotein in mouse organs and budding site at the bronchial epithelium. J Virol 1990;64:3627-3634.
374. Terrier O, Rolland JP, Rosa-Calatrava M, et al. Parainfluenza virus type 5 (PIV-5) morphology revealed by cryo-electron microscopy. Virus Res 2009;142:200-203.
375. Thomas SM, Lamb RA, Paterson RG. Two mRNAs that differ by two nontemplated nucleotides encode the amino coterminal proteins P and V of the paramyxovirus SV5. Cell 1988;54:891-902.
376. Tompkins SM, Lin Y, Leser GP, et al. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology 2007;362:139-150.
377. Tosi MF, Stark JM, Hamedani A, et al. Intercellular adhesion molecule-1 (ICAM-1)-dependent and ICAM-1-independent adhesive interactions between polymorphonuclear leukocytes and human airway epithelial cells infected with parainfluenza virus type 2. J Immunol 1992;149:3345-3349.
378. Toyoda T, Sakaguchi T, Hirota H, et al. Newcastle disease virus evolution. II. Lack of gene recombination in generating virulent and avirulent strains. Virology 1989;169:273-282.
379. Toyoda T, Sakaguchi T, Imai K, et al. Structural comparison of the cleavage-activation site of the fusion glycoprotein between virulent and avirulent strains of Newcastle disease virus. Virology 1987;158:242-247.
380. Tremonti LP, Lin JS, Jackson GG. Neutralizing activity in nasal secretions and serum in resistance of volunteers to parainfluenza virus type 2. J Immunol 1968;101:572-577.
381. Tsurudome M, Bando H, Kawano M, et al. Transcripts of simian virus 41 (SV41) matrix gene are exclusively dicistronic with the fusion gene which is also transcribed as a monocistron. Virology 1991;184:93-100.
382. Tsurudome M, Bando H, Nishio M, et al. Antigenic and structural properties of a paramyxovirus simian virus 41 (SV41) reveal a close relationship with human parainfluenza type 2 virus. Virology 1990;179:738-748.
383. Tyrrell D, Bynoe M, Birkum K, et al. Inoculation of human volunteers with parainfluenza viruses 1 and 3 (HA 2 and HA 1). Br Med J 1959;2:909-911.
384. Tyrrell DA. Some recent trends in vaccination against respiratory viruses. Br Med Bull 1969;25:165-171.
385. Ulane CM, Horvath CM. Paramyxoviruses SV5 and HPIV2 assemble STAT protein ubiquitin ligase complexes from cellular components. Virology 2002;304:160-166.
386. Van Cleve W, Amaro-Carambot E, Surman SR, et al. Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1. Virology 2006;352:61-73.
387. van Wyke Coelingh K, Tierney EL. Antigenic and functional organization of human parainfluenza virus type 3 fusion glycoprotein. J Virol 1989;63:375-382.
388. van Wyke Coelingh KL, Murphy BR, Collins PL, et al. Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirus. Virology 1987;160:465-472.
389. van Wyke Coelingh KL, Winter C, Murphy BR. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. Virology 1985;143:569-582.
390. van Wyke Coelingh KL, Winter CC, Murphy BR. Nucleotide and deduced amino acid sequence of hemagglutinin-neuraminidase genes of human type 3 parainfluenza viruses isolated from 1957 to 1983. Virol 1988;162:137-143.
391. van Wyke Coelingh KL, Winter CC, Tierney EL, et al. Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus. J Virol 1990;64:3833-3843.
392. Varsanyi TM, Kovamees J, Norrby E. Molecular cloning and sequence analysis of human parainfluenza type 2 virus mRNA encoding the fusion glycoprotein. J Gen Virol 1991;72:89-95.
393. Vidal S, Curran J, Kolakofsky D. A stuttering model for paramyxovirus P mRNA editing. Embo J 1990;9:2017-2022.
394. Vigil A, Park MS, Martinez O, et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 2007;67:8285-8292.
395. Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection - myth or reality? Am J Transplant 2003;3:245-249.
396. Warke A, Appleby L, Mundt E. Prevalence of antibodies to different avian paramyxoviruses in commercial poultry in the United States. Avian Dis 2008;52:694-697.
397. Watanabe M, Mishin VP, Brown SA, et al. Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice. Antimicrob Agents Chemother 2009;53:3942-3951.
398. Weinberg GA, Hall CB, Iwane MK, et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 2009;154:694-699.
399. Weinberg GA, Hall CB, Walker FJ, et al. Presented at the Society for Pediatric Research. San Francisco, CA; 2004.
400. Weintrub PS, Sullender WM, Lombard C, et al. Giant cell pneumonia caused by parainfluenza type 3 in a patient with acute myelomonocytic leukemia. Arch Pathol Lab Med 1987;111:569-570.
401. Welliver RC, Wong DT, Middleton E Jr, et al. Role of parainfluenza virus-specific IgE in pathogenesis of croup and wheezing subsequent to infection. J Pediatr 1982;101:889-896.
402. Welliver RC, Wong DT, Sun M, et al. Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis. Am J Dis Child 1986;140:34-40.
403. Wells G, Malur A. Expression of human parainfluenza virus type 3 PD protein and intracellular localization in virus infected cells. Virus Genes 2008;37:358-367.
404. Wolf MC, Freiberg AN, Zhang T, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A 2010;107:3157-3162.
405. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000;182:1331-1342.
406. Xiao S, Paldurai A, Nayak B, et al. Complete genome sequence of avian paramyxovirus type 7 (strain Tennessee) and comparison with other paramyxoviruses. Virus Res 2009;145:80-91.
407. Xiao S, Subbiah M, Kumar S, et al. Complete genome sequences of avian paramyxovirus serotype 6 prototype strain Hong Kong and a recent novel strain from Italy: evidence for the existence of subgroups within the serotype. Virus Res 2010;150:61-72.
408. Yamada H, Hayata S, Omata-Yamada T, et al. Association of the Sendai virus C protein with nucleocapsids. Arch Virol 1990;113:245-253.
409. Yanagihara R, McIntosh K. Secretory immunological response in infants and children to parainfluenza virus types 1 and 2. Infect Immun 1980;30:23-28.
410. Yao Q, Compans RW. Filamentous particle formation by human parainfluenza virus type 2. J Gen Virol 2000;81:1305-1312.
411. Yin HS, Paterson RG, Wen X, et al. Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc Natl Acad Sci U S A 2005;102:9288-9293.
412. Yin HS, Wen X, Paterson RG, et al. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 2006;439:38-44.
413. Young DF, Didcock L, Goodbourn S, et al. Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response. Virology 2000;269:383-390.
414. Yuan P, Thompson TB, Wurzburg BA, et al. Structural studies of the parainfluenza virus 5 hemagglutinin-neuraminidase tetramer in complex with its receptor, sialyllactose. Structure 2005;13:803-815.
415. Zhan X, Slobod KS, Krishnamurthy S, et al. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. Vaccine 2008;26:3480-3488.
416. Zhang L, Bukreyev A, Thompson CI, et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 2005;79:1113-1124.
417. Zhang L, Peeples ME, Boucher RC, et al. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002;76:5654-5666.